

Current studies enrolling at Cedars-Sinai

Disease	Study Drug/ Device	Description	Criteria
HCV			
HCV-naïve	Remicade	IFN + RBV + Remicade vs IFN + RBV + placebo	Genotype 1, Naive
HCV-relapsers	Omega Interferon	RBV + phase I implantable device with continuous infusion of omega IFN	Genotype 1, Relapsers
HCV – naïve, nonresponder, relapser	Eltrombopag	Platelet stimulant + RBV + IFN for patients with platelets too low to treat with PEG/RBV	All genotypes, compensated cirrhotics with low platelets(<75,000); can be naïve, relapsers, non-responders
HCV – naïve, nonresponder	Telapevir	IFN + RBV + protease inhibitor	Genotype 1, naïve or nonresponder
HCV – naïve, nonresponder	Bocepevir	IFN + RBV + protease inhibitor	Genotype 1, naïve or nonresponder
HCV, naïve	SOC HCV	Prospective observational database	Start Standard of care after consent
HCV- insulin resistance	Actos	IFN + RBV + Actos	Genotype 1, with insulin resistance/mild diabetes, treatment naïve
HBV			
HBV – naïve (eAg + or -)	Clevudine	Clevudine vs Adefovir	Treatment naïve
HBV – Lamivudine resistant (eAg + or -)	Combination therapy	Entecavir + Tenofovir vs Adefovir + Lamivudine	Currently on Lamivudine with signs of resistance
HBV- Entecavir naïve (eAg + or -)	Entecavir	Observational study, visits 2x/year	Entecavir naïve
Cirrhosis			
Cirrhosis	Breath Test	Compare liver biopsy results to Breath test results	recent biopsy, or scheduled for a liver biopsy
OLT			
HIV Transplant	(NIH)	Liver transplant for patients with HIV, long term feasibility and outcome study	HIV+ with Cirrhosis Eligible for transplant
HBV post transplant	Truvada	Truvada with/without HBIg in preventing recurrence of HBV post transplant	HBV post OLT
Platelets			
HCV w/ thrombocyt	Eltrombopag	Eltrombo- w/ standard HCV treatment	Platelets < 75, Naïve, or NR due to suboptimal treatment b/c platelets too low
Low Platelets	Eltrombopag	Eltrombopag administration 2 weeks prior to procedure to avoid platelet transfusion	Platelets < 50
Fatty Liver			
NASH	Rimonabant	NASH by biopsy within last 6 months, Daily Rimonabant 20mg with placebo arm	NASH, No viral hepatitis

Contact:

Sandy Leong
Grace Chee
Dawn Rago
Martin Briseno
Teresa DiDiego

Tel: 310 423 5453
Tel: 310 423 5461
Tel: 310 423 9545
Tel: 310 423 7837
Tel: 310 423 5050

sandy.leong@cshs.org
grace.chee@cshs.org
dawn.rago@cshs.org
martin.briseno@cshs.org
teresa.didiego@cshs.org